跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
謝 燿宇
助理教授
,
血液腫瘤科
主治醫師
,
衛生福利部雙和醫院
成員
,
臺北醫學大學癌症轉譯研究中心
https://orcid.org/0000-0003-4368-4281
電子郵件
alecto39
gmail
com
No. 250 Wu-Xing Street, Taipei 11031
h-index
542
引文
15
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
2009
2024
每年研究成果
概覽
指紋
網路
專案
(5)
研究成果
(43)
資料集
(5)
類似的個人檔案
(6)
指紋
查看啟用 Yao-Yu Hsieh 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Cancer
100%
Malignant Neoplasm
93%
Epidermal Growth Factor Receptor
71%
Biological Marker
65%
Chemotherapy
55%
Pancreas Adenocarcinoma
53%
Cetuximab
53%
Cisplatin
53%
Drug Resistance
52%
Repurposing
44%
Chronic Myeloid Leukemia
43%
Imatinib
40%
Overall Survival
37%
Prevalence
35%
Bile Duct Carcinoma
35%
Head and Neck Squamous Cell Carcinoma
35%
Progression Free Survival
30%
Neoplasm
30%
Carcinogenesis
27%
Drug Repositioning
26%
Colorectal Carcinoma
25%
Sarcoma
23%
Metastatic Breast Cancer
22%
Histone Deacetylase Inhibitor
20%
Etoposide
20%
Phosphotransferase Inhibitor
20%
Protein Tyrosine Kinase Inhibitor
19%
Oxaliplatin
19%
Cohort Study
18%
Phosphatase
17%
Piper Betle
17%
4 Amino 6 [2 [[4 (Diethylamino) 1 Methylbutyl]amino] 6 Methyl 4 Pyrimidinyl] 2 Methylquinoline
17%
Fedratinib
17%
Lung Cancer
17%
Antibiotic Prophylaxis
17%
Immunogenic Cell Death
17%
Cytoprotective Agent
17%
Vinorelbine
17%
Lapatinib
17%
Hypophysis Tumor
17%
Renal Cell Carcinoma
17%
Liver Cirrhosis
17%
Digestive System Cancer
17%
Gefitinib
17%
Transcription Factor EZH2
17%
Tensin
17%
Pancytopenia
17%
Epidermal Growth Factor
17%
Synovial Sarcoma
17%
Insulin Dependent Diabetes Mellitus
17%
Medicine and Dentistry
Epidermal Growth Factor Receptor
53%
Cholangiocarcinoma
53%
Biological Marker
44%
Overall Survival
40%
Oxaliplatin
37%
Azacitidine
35%
Prevalence
35%
Drug Action
35%
Decitabine
35%
Medicine
35%
Cisplatin
35%
Malignant Neoplasm
27%
Oncology
27%
Chronic Myelogenous Leukemia
25%
Hazard Ratio
25%
Cancer Cell
23%
In Vitro
23%
K562 Cells
22%
Imatinib
22%
Carcinogenesis
21%
Prognostic Factor
21%
Surgery
20%
Programmed Cell Death
20%
Phosphotransferase Inhibitor
20%
Retrospective Cohort Study
18%
Hematology
17%
Division
17%
Internal Medicine
17%
Insulin Dependent Diabetes Mellitus
17%
Immune Checkpoint Inhibitor
17%
Leukemia Cell
17%
Renal Cell Carcinoma
17%
Histone Deacetylase Inhibitor
17%
B-Cell Lymphoma
17%
Tyrosine-Kinase Inhibitor
17%
Risk Stratification
17%
Knock Out
17%
Colorectal Liver Metastasis
17%
Irinotecan
17%
Synovial Sarcoma
17%
Diabetic Ketoacidosis
17%
Upper Gastrointestinal Bleeding
17%
Head and Neck Squamous Cell Carcinoma
17%
Liver Cirrhosis
17%
Bone Metastasis
17%
Antibiotic Prophylaxis
17%
Lymphoma Cell
17%
Prostate Cancer
17%
HDAC1
17%
Fluorouracil
17%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
77%
Epidermal Growth Factor Receptor
53%
Myeloid
45%
Imatinib
40%
Drug Resistance
40%
Computer Model
35%
Cisplatin
35%
Overall Survival
30%
Carcinogenesis
26%
Progression Free Survival
26%
Cell Death
25%
K562 Cells
24%
Exon
23%
Gene Expression
23%
Tumor Progression
22%
KRAS
22%
Doxorubicin
21%
Anticancer
20%
Autophagy
20%
Tyrosine Kinase Inhibitor
19%
Unfolded Protein Response
17%
Oncogene
17%
Cell Cycle
17%
Surface Property
17%
RRM2
17%
Interferon
17%
Gemcitabine
17%
ABL (Gene)
17%
Transcription Factor EZH2
17%
Mesenchymal-Epithelial Transition
17%
IRF1
17%
BCL6
17%
Drug Mechanism
17%
Myc
17%
Wild Type
17%
Prevalence
17%
Carbamoyl Phosphate Synthetase I
17%
Decitabine
17%
Cyclin-Dependent Kinase
17%
Histone Deacetylase
17%
Topoisomerase
17%
DNA Topoisomerase
17%
Antineoplastic Activity
17%
Azacitidine
17%
Urea Cycle
17%
interferon
17%
Ribonucleotide Reductase
17%
Calreticulin
17%
Transforming Growth Factor
17%
Long Non-Coding RNA
17%